Skip to main content

Santarus applies for approval of ulcerative colitis drug


SAN DIEGO — Drug maker Santarus has submitted a new drug application with the Food and Drug Administration for a treatment for ulcerative colitis, the company said.

The application was for Uceris (budesonide) tablets in the 9-mg strength for moderate active UC. The company is developing the drug under a collaboration with Cosmo Technologies.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

This ad will auto-close in 10 seconds